First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt) - Siefker-Radtke, A O; Necchi, A; Park, S H (J Clin Oncol, 2018)
et al.